Meisner Lara 4
4 · Bicara Therapeutics Inc. · Filed Oct 1, 2025
Insider Transaction Report
Form 4
Meisner Lara
Chief Legal Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-29−33,807→ 101,423 totalExercise: $9.24Exp: 2034-08-13→ Common Stock (33,807 underlying) - Exercise/Conversion
Common Stock
2025-09-29$9.24/sh+33,807$312,495→ 33,807 total - Sale
Common Stock
2025-09-29$14.75/sh−33,807$498,653→ 0 total
Footnotes (2)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.
- [F2]25% of the shares underlying this option vested on August 13, 2025, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.